Made With Uberflip Content Marketing

Latest Content

Insight provides timely coverage of news that influences the business strategies of the life science industry. It is also the source for up-to-date information on leading industry partnering events.

  • Mounting uncertainty threatens research and innovation in medicines

    Mounting uncertainty threatens research and innovation in medicines

    Regulatory reforms, political upheavals and proposed cuts to research funding create an uncertain and increasingly risky landscape for companies developing new medicines. The life sciences...

    Read
  • ×

    Download "Digital Medicine Connect" Whitepaper

    First Name
    Last Name
    Thank you! Enjoy!
    Error - something went wrong!
  • Can pharma afford to cure patients instead of treating them?

    Can pharma afford to cure patients instead of treating them?

    Who wants a one-shot therapy that delivers a durable response in patients? What is the price for a cure that payers are willing to pay? Why is pharma turning its attention away from this...

    Read
  • Biotechs successfully navigate alternative paths to financing

    Biotechs successfully navigate alternative paths to financing

    Project awards, strategic venture funds and now crowd-funding offer alternatives to traditional venture funds for emerging biotech companies. Pfizer's new strategic fund or the well-established...

    Read
  • Join us at BIO-Europe Spring 2017 this March

    Learn More
  • POLs: Patient opinion leaders emerge as key to success in orphan drug designation

    POLs: Patient opinion leaders emerge as key to success in orphan drug designation

    Orphan drugs are wicked hot. Wall Street loves them. And patients are a powerful force that can make or break a decision to grant that coveted designation for your drug. But don't count on having...

    Read
  • Facing increased complexity, oncology trial sites tighten up procedures

    Facing increased complexity, oncology trial sites tighten up procedures

    Financing a Phase I trial in oncology is tough, but completing a successful trial for a novel drug candidate is even tougher. An army of specialists is required, and then comes the challenge of...

    Read
  • Digital medicine takes small steps toward Big Data

    Digital medicine takes small steps toward Big Data

    Across a fragmented European landscape multiple programs advance the digitization of data as building blocks for advanced analytics. Read more »

    Read
  • Startup Slam: Compelling pitch for Peptomyc takes the prize

    Startup Slam: Compelling pitch for Peptomyc takes the prize

    The third round of this fast-paced parade of presentations pitted 14 promising entrepreneurs in a winner-take-all competition. The reward includes tailored mentoring with the scientists and...

    Read
  • BIO Report: Funding cools down after five-year run while early deals stay hot

    BIO Report: Funding cools down after five-year run while early deals stay hot

    Across five metrics for biotech financings tracked by BIO, the sector saw steep drops in 2016 due to uncertainty introduced by political upheavals and regulatory reforms. Yet in each category the...

    Read
  • BIO-Europe Spring 2017 kicks off this week in Barcelona

    BIO-Europe Spring 2017 kicks off this week in Barcelona

    Read
  • Report gives substance to fast-paced scientific discoveries in microbiome

    Report gives substance to fast-paced scientific discoveries in microbiome

    Guest post by Eric de La Fortelle, Venture Partner at Seventure Partners Microbes are everywhere, and apart from the occasional pathogen, they are a positive force for health maintenance. Indeed...

    Read
  • Join us at the Inaugural Cell & Gene Exchange this May 2017

    Learn More
  • ×

    Download "Finding Finance" Industry report

    First Name
    Last Name
    Thank you!
    Error - something went wrong!
  • 2016 – A Year in Review for Advanced Therapies

    2016 – A Year in Review for Advanced Therapies

    Guest post by Patricia Reilly, M.S., Head of Intelligence Alliances and Unification, Pharma Intelligence | Informa The past year saw intensifying dialogue on how to assess the value of and...

    Read
  • Stirring the Pot for Entrepreneurship in European Tech Transfer

    Stirring the Pot for Entrepreneurship in European Tech Transfer

    Guest post by Luke Timmerman, founder and editor of the Timmerman Report, and a regular contributor to Forbes and STAT News. The science in many parts of Europe is first-rate. No one disputes...

    Read
  • World RARE Disease Day shines a light on rare disease community

    World RARE Disease Day shines a light on rare disease community

    Tomorrow is the 10th annual World RARE Disease Day. Various activities are taking place all over the United States as well as countless locations around the world. World RARE Disease Day is an...

    Read
  • Barcelona biotech companies shine light on regional entrepreneurship

    Barcelona biotech companies shine light on regional entrepreneurship

    Investors are always on the lookout for innovative biotech startups, and the Catalonia, Spain biopharma cluster has plenty to offer in the way of innovation from among its member companies....

    Read
  • Increase the value of your asset: Think with the end in mind

    Increase the value of your asset: Think with the end in mind

    Developing a drug is a very long journey, therefore it is critical to define the destination upfront. The Target Product Profile is like a postcard of your desired destination. It informs the data...

    Read
  • What’s the deal with Immuno-oncology partnering?

    What’s the deal with Immuno-oncology partnering?

    Insight wanted to get the lay of the I/O landscape, so who better to speak with than Jeff Bockman, Vice President of Defined Health. Not only was Jeff kind enough to share his insights with us,...

    Read
  • Why the connected patient is the killer app in the digital age of medicine

    Why the connected patient is the killer app in the digital age of medicine

    Guest article by Deb Kilpatrick, PhD, CEO at Evidation Health and Rich Milani, MD, FACC, FAHA, Chief Clinical Transformation Officer at Ochsner Health System If you search on the phrase “killer...

    Read
  • Barcelona’s GP Pharm considers partnering key to international expansion

    Barcelona’s GP Pharm considers partnering key to international expansion

    Barcelona is an attractive location for business and trade, and has experienced a revival in the biopharma sector in recent years with the outsourcing of innovation from pharma companies to...

    Read
  • Welcome to Barcelona—one of the most vibrant life sciences hubs in Europe

    Welcome to Barcelona—one of the most vibrant life sciences hubs in Europe

    Guest article by BIOCAT, the Bioregion of Catalonia After the great success of previous editions (2010 and 2013), the Bioregion of Catalonia is again hosting BIO-Europe Spring® 2017 (March 20–22),...

    Read
  • Realities of Rare Disease and the Role of Patient Investors

    Realities of Rare Disease and the Role of Patient Investors

    Guest post by Nicole Boice, Founder & CEO, Global Genes – Allies in Rare Disease Rare Disease represents the largest disease community on the planet!  With over 7,000 identified diseases,...

    Read
  • Finding Finance: Pharma, Biotech & Medtech Capital Raising 2016

    Finding Finance: Pharma, Biotech & Medtech Capital Raising 2016

    Read Flipbook
  • Digital medicine: Invest in innovation

    Digital medicine: Invest in innovation

    It’s too soon to say, definitively, whether digital medicine will be disruptive or adjunctive for drug developers or even the entire healthcare system. Even the business models are in flux. What...

    Read
  • DIGITAL-MEDICINE-WHITEPAPER

    DIGITAL-MEDICINE-WHITEPAPER

    Read Flipbook
  • Pharma Industry Report: Top 10 Drugs

    Pharma Industry Report: Top 10 Drugs

    Read Flipbook
  • How Do Healthcare Investors and Payers Separate the Tools From the Toys?

    How Do Healthcare Investors and Payers Separate the Tools From the Toys?

      Guest post by Nicole Fisher, Founder & CEO at HHR Strategies, Inc., Forbes Contributor The healthcare sector does not behave like other industries when it comes to money. First, attracting...

    Read
  • Partnering in the Pharma World: BIO-Europe® and industry trends 2012-2015

    Partnering in the Pharma World: BIO-Europe® and industry trends 2012-2015

    Read Flipbook
  • UK Establishment upbeat about Brexit’s effect on British life science industry

    UK Establishment upbeat about Brexit’s effect on British life science industry

    Brexit may no longer be at the top of popular news, but it continues to be a key concern for biopharma companies in post-Brexit 2017. The sentiment of key players from the UK life sciences from a...

    Read
  • Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta10:13

    Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta

    Following submission of new drug application of Zilretta (FX006) for knee osteoarthritis in mid-December 2016, Flexion Therapeutics CEO Mike Clayman is hoping for priority review of the filing, in add

    Watch Video
  • Finding the value of real-world evidence

    Finding the value of real-world evidence

    Real-world evidence isn’t about what happens in the clinic, but is just as important to your success. It’s the application of analytics to real-world data collected outside the realm of...

    Read
  • Taming the Wild West of digital medicine

    Taming the Wild West of digital medicine

    The new paradigm of healthcare is widely becoming known as “The Digital Health Revolution,” referring to medical technology advancements so great that when combined with wearables, medication...

    Read
  • Investors’ appetite for the life sciences continued in 2016

    Investors’ appetite for the life sciences continued in 2016

    Guest post by Doro Shin, Thought Leadership Manager at Informa Pharma Intelligence While 2015 was a record year for investments within the life sciences industry, investors became wary toward the...

    Read
  • Rare diseases, rare commitment

    Rare diseases, rare commitment

    Patients, their families and patient foundations are invaluable in helping drug developers understand the day-to-day realities of approx. 7,000 rare diseases (of which only 400 have therapies)....

    Read
  • Biotech Showcase™ 2017: J&J poised to establish no-strings-attached JLABS outside America8:28

    Biotech Showcase™ 2017: J&J poised to establish no-strings-attached JLABS outside America

    As Johnson & Johnson announced the establishment of its eighth JLABS facility, in collaboration with New York State and the New York Genome Center, Melinda Richter, head of Johnson & Johnson Innovatio

    Watch Video
  • Thirteen young people bucking the odds, finding paths to break into biotech

    Thirteen young people bucking the odds, finding paths to break into biotech

    Guest post by Luke Timmerman, founder and editor of the Timmerman Report, and a regular contributor to Forbes and STAT News. Walking around San Francisco’s Union Square during biotech conference...

    Read
  • Digital Health Security: The Most Important Tradeoff Between Ease and Privacy

    Digital Health Security: The Most Important Tradeoff Between Ease and Privacy

    Guest post by Nicole Fisher, Founder & CEO at HHR Strategies, Inc., Forbes Contributor Wayne Gretzky always said it’s better to look where the puck is going, not where it is now. The introduction...

    Read
  • The state of cell and gene therapy: Reimbursement and manufacturing dominate

    The state of cell and gene therapy: Reimbursement and manufacturing dominate

    The number of cell therapies in clinical trials has grown 21 percent since 2015, with more than 759 trials underway globally. With that growth it is time for the industry to get serious about...

    Read
  • Biotech Showcase™ 2017: Reinventing Arena to focus on Phase II clinical candidates6:06

    Biotech Showcase™ 2017: Reinventing Arena to focus on Phase II clinical candidates

    In the six months after joining Arena Pharmaceuticals as CEO, Dr. Amit Munshi has been busy: reducing the company’s commitment to obesity drug Belviq, which it has partnered with Eisai; spinning out t

    Watch Video
  • Industry pundit Joe Hage on medtech innovation in 2017

    Industry pundit Joe Hage on medtech innovation in 2017

    Joe Hage, a medical device marketing consultant, is well known in medtech circles. In particular, he runs one of the largest and possibly most successful LinkedIn groups, the “Medical Devices...

    Read
  • Digital Health: Smart Devices Were Just The Beginning

    Digital Health: Smart Devices Were Just The Beginning

    The connectivity that will be created by the convergence of computers and health will truly alter the way knowledge, technology and insights into the future revolutionize health care.

    Read
  • Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 20174:24

    Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 2017

    An increased focus on the need to access and develop truly transformational medicines was a key theme in the hallway chatter at this year’s Biotech Showcase/JP Morgan Healthcare meetings. Michael Hay,

    Watch Video
  • Unmet needs, uncommon commitment: The shift toward investment in rare diseases

    Unmet needs, uncommon commitment: The shift toward investment in rare diseases

    Join biotech leaders, emerging innovators, investors and patient advocacy group reps for a candid, interactive and enlightening discussion about rare disease drug discovery and development. Read...

    Read
  • Biotech Showcase™ 2017: Unmet needs, uncommon commitment: The shift toward investment in rare diseas1:03:52

    Biotech Showcase™ 2017: Unmet needs, uncommon commitment: The shift toward investment in rare diseas

    Join biotech leaders, emerging innovators, investors and patient advocacy group representatives for a candid, interactive and enlightening panel discussion about the evolving landscape in rare disease

    Watch Video
  • Pulse, prognosis and the press: Journalists discuss key biotech trends for 2017

    Pulse, prognosis and the press: Journalists discuss key biotech trends for 2017

    As the intensity of Biotech Week in San Francisco winds down, join our exclusive panel of all-star reporters for their unique take on the news, trends and issues that will reverberate in 2017 and...

    Read
  • Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?

    Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?

    Amid tirelessly pursuing possible partnerships and investment opportunities to bring revolutionary medical products to market at Biotech Showcase™ 2017 in San Francisco, global executives were...

    Read
  • Innovation in an uncertain world

    Innovation in an uncertain world

    How are cutting-edge biotech companies trying to compete in a global marketplace dealing with drug-price anger, science skepticism, and policies to close borders and protect jobs? Read more »

    Read
  • Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients7:53

    Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients

    Brain cancer remains one of the deadliest diseases, and little to no effective treatments exist. Marty Duvall, newly appointed CEO of San Diego-based gene therapy technology company Tocagen, tells Mik

    Watch Video
  • Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception9:11

    Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception

    With readouts in important trials of key drugs Invokana and Xarelto on the horizon, Dr. James F. List, Global Therapeutic Area Head of Cardiovascular and Metabolism, has plenty of reasons for insomnia

    Watch Video
  • Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML12:05

    Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML

    Following a Phase II release of data for its oral histone deacetylase (HDAC) inhibitor pracinostat in the tough-to-treat acute myeloid leukemia (AML), MEI Pharma CEO Dan Gold says he is optimistic hea

    Watch Video
  • Biotech Showcase™ 2017: Second Genome CEO predicts paradigm shift with microbiome discovery8:05

    Biotech Showcase™ 2017: Second Genome CEO predicts paradigm shift with microbiome discovery

    Microbiome discovery and development will trigger the next major paradigm shift in medicine, more profound than the discovery of recombinant DNA, Second Genome CEO Glenn Nedwin predicted in an intervi

    Watch Video
  • Biotech Showcase™ 2017: PhaseRx makes more noise than silence with mRNA delivery8:05

    Biotech Showcase™ 2017: PhaseRx makes more noise than silence with mRNA delivery

    Having ditched RNA silencing in 2012, PhaseRx president and CEO Dr. Robert Overell explains to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, how delivering

    Watch Video
  • It’s all happening at Biotech Showcase™ Week

    It’s all happening at Biotech Showcase™ Week

    Guest post by Constantine Theodoropulos, President, GO Therapeutics Thankfully there is a holiday between now and Biotech Showcase™ Week in San Francisco (Jan 9–11), because we are going to need...

    Read
  • Biotech Showcase™ 2017: CBMG aims for large-scale CAR-T capacity9:36

    Biotech Showcase™ 2017: CBMG aims for large-scale CAR-T capacity

    Cellular Biomedicine Group (CBMG) CEO Bizuo (Tony) Liu differentiates plans for chimeric antigen receptor-T cell development in part by large-scale production in the company's home country, China. In

    Watch Video
  • Lifetime trends in biopharmaceutical innovation: Recent evidence and implications

    Lifetime trends in biopharmaceutical innovation: Recent evidence and implications

    Guest blog post by Murray Aitken, Executive Director of the QuintilesIMS Institute Adequate returns on life sciences investments underpin the sustainability of the innovation lifecycle.   And...

    Read
  • Breaking news:  Creating a healthcare futures market

    Breaking news: Creating a healthcare futures market

    Dennis Purcell, founder and senior advisor of Aisling Capital LLC, and co-founder of Poliwogg, is creating a futures market for healthcare, mirroring healthcare consumption from diagnosis to...

    Read
  • The renaissance of gene therapy

    The renaissance of gene therapy

    Gene therapy and gene editing are at the beginning of a renaissance, according to speakers at Biotech Showcase™ 2017. While sizeable challenges exist, they are being overcome, leaving the field...

    Read
  • loading
    Loading More...